Belumosudil mesylate

甲磺酸贝舒地尔

Report date: 2026/04/22 20:01:10
NME

Base Information

Drug NameBelumosudil mesylate
Drug Alias NameKD025 mesylate贝舒地尔BelumosudilRezurockRholistiq +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRho-associated protein kinase 2 inhibitors
TargetsRho-associated protein kinase 2
Therapy Area/IndicationsPlaque psoriasisRejection of renal transplantationRejection of lung transplantation +[17] 
Global Approved IndicationsGraft vs Host Disease
Approved Indications in ChinaGraft vs Host Disease
Original Approved Country/TerritoryUnited States
Original Approved Date2021/07/16
Country/TerritoryCzechiaBelgiumCanada +[29] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNabriva Therapeutics PlcKadmon Corporation Llc
China Registration ClassN/A

Develop Information

Active CompaniesBionova Pharmaceuticals (Shanghai) LtdKadmon Pharmaceuticals LLCSanofi +[11] 
Inactive CompaniesBk Pharmaceuticals LtdSanofi-Aventis Recherche & Developpement
Active IndicationsRejection of renal transplantationRejection of lung transplantationGraft vs Host Disease +[9] 
Inactive IndicationsPlaque psoriasisFibrosisAutoimmune Diseases +[8] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG